OBJECTIVE: To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. METHODS: In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. RESULTS: The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. CONCLUSIONS: Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.
OBJECTIVE: To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. METHODS: In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. RESULTS: The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. CONCLUSIONS: Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.
Authors: Gordon J S Rustin; Michael Quinn; Tate Thigpen; Andreas du Bois; Eric Pujade-Lauraine; Anders Jakobsen; Elizabeth Eisenhauer; Satoru Sagae; Kathryn Greven; Ignace Vergote; Andres Cervantes; Jan Vermorken Journal: J Natl Cancer Inst Date: 2004-03-17 Impact factor: 13.506
Authors: Helen J Mackay; Mark F Brady; Amit M Oza; Alexander Reuss; Eric Pujade-Lauraine; Ann M Swart; Nadeem Siddiqui; Nicoletta Colombo; Michael A Bookman; Jacobus Pfisterer; Andreas du Bois Journal: Int J Gynecol Cancer Date: 2010-08 Impact factor: 3.437
Authors: A du Bois; M Quinn; T Thigpen; J Vermorken; E Avall-Lundqvist; M Bookman; D Bowtell; M Brady; A Casado; A Cervantes; E Eisenhauer; M Friedlaender; K Fujiwara; S Grenman; J P Guastalla; P Harper; T Hogberg; S Kaye; H Kitchener; G Kristensen; R Mannel; W Meier; B Miller; J P Neijt; A Oza; R Ozols; M Parmar; S Pecorelli; J Pfisterer; A Poveda; D Provencher; E Pujade-Lauraine; M Randall; J Rochon; G Rustin; S Sagae; F Stehman; G Stuart; E Trimble; P Vasey; I Vergote; R Verheijen; U Wagner Journal: Ann Oncol Date: 2005 Impact factor: 32.976
Authors: Robert C Bast; J Tate Thigpen; Susan G Arbuck; Karen Basen-Engquist; Laurie B Burke; Ralph Freedman; Sandra J Horning; Robert Ozols; Gordon J Rustin; David Spriggs; Lari B Wenzel; Richard Pazdur Journal: Gynecol Oncol Date: 2007-11 Impact factor: 5.482
Authors: H B Salvesen; S L Carter; M Mannelqvist; A Dutt; G Getz; I M Stefansson; M B Raeder; M L Sos; I B Engelsen; J Trovik; E Wik; H Greulich; T H Bø; I Jonassen; R K Thomas; T Zander; L A Garraway; A M Oyan; W R Sellers; K H Kalland; M Meyerson; L A Akslen; R Beroukhim Journal: Proc Natl Acad Sci U S A Date: 2009-03-04 Impact factor: 11.205
Authors: Keith L Knutson; Matthew J Maurer; Claudia C Preston; Kirsten B Moysich; Krista Goergen; Kieran M Hawthorne; Julie M Cunningham; Kunle Odunsi; Lynn C Hartmann; Kimberly R Kalli; Ann L Oberg; Ellen L Goode Journal: Cancer Immunol Immunother Date: 2015-08-23 Impact factor: 6.968
Authors: Xu Liu; Yuan Zhang; Ling-Long Tang; Quynh Thu Le; Melvin L K Chua; Joseph T S Wee; Nancy Y Lee; Brian O'Sullivan; Anne W M Lee; Ying Sun; Jun Ma Journal: JAMA Oncol Date: 2018-08-01 Impact factor: 31.777
Authors: Claudia C Preston; Matthew J Maurer; Ann L Oberg; Daniel W Visscher; Kimberly R Kalli; Lynn C Hartmann; Ellen L Goode; Keith L Knutson Journal: PLoS One Date: 2013-11-14 Impact factor: 3.240